Literature DB >> 12063554

Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis.

B Washburn1, V Schirrmacher.   

Abstract

In order to analyse immune-stimulatory effects of infection of human tumor cells with Newcastle Disease Virus (NDV), gamma-irradiated human breast carcinoma, colon-carcinoma or glioblastoma cells from defined cell lines were modified either by true infection with live virus or by cell surface adsorption of UV-inactivated replication deficient virus. Modification with live but not inactive NDV induced in all human tumor cells IFN-beta and the chemokines RANTES and IFN-gamma-inducible protein-10 (IP-10). In addition, infection by live NDV induced upregulation of HLA-ABC-molecules in all tumor lines tested and HLA-DR molecules in breast carcinoma lines. Two cell adhesion molecules, ICAM-I (CD54) and LFA-3 (CD58), were also upregulated on human tumor cells after infection with live NDV. When infection of MCF-7 breast carcinoma cells by NDV was performed in the presence of neutralizing anti-IFN-beta antibodies no upregulation of HLA molecules was observed suggesting an important role of IFN-beta in this process. Forty-eight to 72 hours after infection of the irradiated tumor cells with live NDV, many tumor cells were dead or in early or late stages of apoptosis. These results provide explanations for the function of the virus-modified autologous tumor vaccine ATV-NDV with which promising clinical results have already been obtained.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063554     DOI: 10.3892/ijo.21.1.85

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  33 in total

Review 1.  Vaccination in the immunotherapy of glioblastoma.

Authors:  Ziren Kong; Yu Wang; Wenbin Ma
Journal:  Hum Vaccin Immunother       Date:  2017-12-11       Impact factor: 3.452

2.  Cell-type-specific innate immune response to oncolytic Newcastle disease virus.

Authors:  Moanaro Biswas; Sandeep R P Kumar; Adria Allen; Wang Yong; Ramadevi Nimmanapalli; Siba K Samal; Subbiah Elankumaran
Journal:  Viral Immunol       Date:  2012-07-18       Impact factor: 2.257

Review 3.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

4.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

5.  Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Authors:  Sateesh Krishnamurthy; Toru Takimoto; Ruth Ann Scroggs; Allen Portner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells.

Authors:  Mena Mansour; Peter Palese; Dmitriy Zamarin
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

7.  Newcastle disease virus V protein is a determinant of host range restriction.

Authors:  Man-Seong Park; Adolfo García-Sastre; Jerome F Cros; Christopher F Basler; Peter Palese
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Combined therapy of oncolytic Newcastle disease virus and rhizomes extract of Rheum ribes enhances cancer virotherapy in vitro and in vivo.

Authors:  Ahmed Majeed Al-Shammari; Raghad Dhyea Abdul Jalill; Mohammed F Hussein
Journal:  Mol Biol Rep       Date:  2020-01-22       Impact factor: 2.316

9.  Genetically engineered Newcastle disease virus for malignant melanoma therapy.

Authors:  D Zamarin; A Vigil; K Kelly; A García-Sastre; Y Fong
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

Review 10.  Oncolytic virus therapy for cancer.

Authors:  Joe Goldufsky; Shanthi Sivendran; Sara Harcharik; Michael Pan; Sebastian Bernardo; Richard H Stern; Philip Friedlander; Carl E Ruby; Yvonne Saenger; Howard L Kaufman
Journal:  Oncolytic Virother       Date:  2013-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.